Upgrade to SI Premium - Free Trial

Audentes Therapeutics (BOLD) Announces Update on ASPIRO Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy

August 7, 2018 6:23 AM
Audentes Therapeutics, Inc. (NASDQ: BOLD) today reported its financial results for the second quarter ended June 30, 2018 and provided ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles